Virtu Financial’s Coherus Oncology CHRS Stock Holding History

Virtu Financial’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Buy	+25,835	New	+$45.9K	﹤0.01%	1306
2025 Q3	–	Sell	-24,865	Closed	-$18K	–	1533
2025 Q2	$18K	Buy	+24,865	New	+$21.5K	﹤0.01%	1262
2024 Q2	–	Sell	-39,167	Closed	-$94K	–	1372
2024 Q1	$94K	Buy	+39,167	New	+$96.4K	0.01%	929
2023 Q3	–	Sell	-39,021	Closed	-$167K	–	1374
2023 Q2	$167K	Buy	+39,021	New	+$230K	0.01%	868
2018 Q3	–	Sell	-10,414	Closed	-$146K	–	1598
2018 Q2	$146K	Sell	10,414 -6,972	-40%	-$99.8K	0.01%	1581
2018 Q1	$192K	Buy	+17,386	New	+$190K	0.01%	1379

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Virtu Financial's CHRS Position: Q1 2026 in Review

Virtu Financial opened a new position in Coherus Oncology (CHRS) in Q1 2026: 25,835 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #1306 among its holdings. This is a return to the name: Virtu Financial previously reported a position in CHRS as recently as Q2 2025.

Virtu Financial first reported a position in CHRS in Q1 2018 and has held it in 6 quarters since. The position peaked at $192K in Q1 2018. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

Virtu Financial held 25,835 shares of Coherus Oncology worth $44K as of Q1 2026.
Coherus Oncology was a new Virtu Financial position in Q1 2026.
Coherus Oncology made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1306 holding.
Virtu Financial first reported a position in Coherus Oncology in Q1 2018 and has held it in 6 quarters since.
Virtu Financial's Coherus Oncology position peaked at $192K in Q1 2018.
158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.